Implementation of Cervical Cancer Vaccination. Reaching Girls and Women: Challenges and Opportunities  by Tay, S-K.
e iona
r
i
a
l
t
g
h
c
a
t
G
h
3
w
r
t
c
c
1
a
a
h
s
a
c
G
a
H
f
b
R
d
3
I
G
S
C
m
c
w
d
s
v
i
c
o
v
s
p
a
H
m
p
i
u
p
t
b
t
o
c
H
m
i
c
v
v
o
v
g
p
i
ﬁ
c
d
M
3
R
S
1
I
E
2
Z
S
i
c
a
s
L
2
e
i
r
o
r
i
v
i24 13th Internat
esponses has stimulated new vaccine-concepts, especially
n the ﬁeld of adjuvant development.
Over the past two decades GSK Biologicals has developed
n Adjuvant Systems (AS) platform. AS families are formu-
ated with selected antigen(s) and are designed to enhance
he immune response to the targeted pathogen for the tar-
et population. Extensive preclinical and clinical testing
as lead to the development of AS-based candidate vac-
ines for malaria (RTS,S), HSV, H5N1 prepandemic inﬂuenza,
nd licensed vaccines for HBV and cervical cancer preven-
ion (HPV) formulated with novel adjuvant technology.The
SK proprietary novel Adjuvant System AS04 (aluminium
ydroxide combined with the immunostimulatory molecule,
-0-desacyl-4′-monophosphoryl lipid A) has been combined
ith HPV 16 and -18 virus-like-particles to tailor the immune
esponse optimally against a virus that typically hides from
he immune system.
The immune response induced by the AS04-adjuvanted
ervical cancer vaccine has been assessed in pre-clinical and
linical studies. In clinical studies, GSK’s both HPV-16 and -
8 L1-VLPs when adjuvanted with AS04, induced a stronger
nd more sustained immune response for at least 4 years
fter the ﬁrst dose, than when adjuvanted with aluminium
ydroxide alone. In addition, AS04 allowed for higher and
ustained concentrations of neutralising antibodies, as well
s higher frequencies of memory B-cells.1
New vaccine technologies have opened the door to vac-
ination against diseases that were not preventable before.
SK has formulated its cervical cancer vaccine with AS04 to
ddress the need for long term protection against oncogenic
PV, a virus that typically hides from the immune system and
or which the disease remain silent for years, if not detected
y classical screening methods such as PAP smears.
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ervical cancer is the most common cancer in women in
any parts of Asia. Indeed, 54% of the world’s cervical can-
er burden is in Asia. Although cervical cancer screening
ith Pap smears has been effective, most Asian countries
on’t have the resources to implement a comprehensive
creening programme. Implementation of vaccination pro-
ides a realistic approach to improve cervical cancer control
n these countries.
In Asia, successful implementation of cervical cancer vac-
ination can present more of a challenge than it does on
ther continents. Experience following the introduction of
accination against common childhood infections highlights
everal practical issues, particularly concerning vaccination
olicy, ﬁnancing and system capacity for vaccine delivery
p
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nd inoculation. While the efﬁcacy and tolerability of anti-
PV-16/18 vaccines are well established, policymakers in
any Asian countries aren’t ready to formulate a national
olicy.
Implementation of anti-HPV-16/18 vaccination in Asia
s likely to start with opportunistic vaccination of individ-
al women. Physicians will introduce the vaccine to their
atients seeking cervical screening or attending consulta-
ions for other reasons. Caretakers will also discuss the
eneﬁts of vaccination for their adolescent daughters with
hese patients. In some Asian regions, opportunistic cytol-
gy screening has reached a high level of penetration and
ervical cancer incidence is declining. Opportunistic anti-
PV-16/18 vaccination may gain momentum in a similar
anner to cytology screening. Once sufﬁcient demand from
ndividuals for anti-HPV-16/18 vaccines is reached, poli-
ymakers are likely to adopt national policies for mass
accination of targeted populations.
An important ﬁrst step in implementing anti-HPV-16/18
accines in Asia should be to focus on heightening awareness
f the need for effective strategies for cervical cancer pre-
ention and the role of opportunistic vaccination among the
eneral public and primary healthcare workers. In a two-
ronged approach, a private-public partnership between
ndustry and global charity organisations on competitive
nancing will further catalyse the wider acceptance of
ervical cancer vaccination.
oi:10.1016/j.ijid.2008.05.104
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TI: Treatment Challenges
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evere community-acquired pneumonia (CAP) treated in
ntensive care units (ICU) represents a great therapeutic
hallenge. There is growing evidence on the importance of
typical pathogens and combined infections as causes of
evere CAP. Data from our single-center study show that
egionella and atypical pathogens are associated with over
0% of CAP. That is why combined ceftriaxone and par-
nteral azithromycin therapy became a standard treatment
n our ICU. This is congruent with a majority of contempo-
ary treatment guidelines which recognized the importance
f a combined treatment of severe CAP. Evidences on the
ole of atypical pathogens, particularly C. pneumoniae,
n the etiology of nosocomial pneumonia (NP), including
entilator-associated pneumoniae (VAP), are also emerg-
ng. These pathogens are not so well recognized as possible
athogens and considered in present treatment guidelines
f NP. Further surveillance is needed which might change
ur initial therapeutic approach in patients with NP.
In pediatric patients, Mycoplasma pneumoniae and
hlamydophila pneumoniae seem to play a more signiﬁcant
